

Our Corporate Responsibility 2016 – GRI Index

Preparation of CSL Limited's Our Corporate Responsibility 2016 Report followed the Global Reporting Initiative's (GRI) G4 Sustainability Reporting Guidelines. We have self-assessed our report as in accordance core to GRI G4's Guidelines.

General Standard Disclosures		
Indicator	Description	CSL's Response
Strategy and Analysis		
G4-1	Statement from the CEO	Message from the CEO & Managing Director
Organisational Profile		
G4-3	Name of organisation	Section 1
G4-4	Primary brands, products, and services	Visit www.csl.com.au
G4-5	Location of headquarters	Section 1
G4-6	Countries of operation	Section 1
G4-7	Nature of ownership and legal form	Section 1
G4-8	Markets served	Section 1
G4-9	Scale of the organisation	Section 1
G4-10	Workforce overview	Section 1.5 Contractor numbers are not available for the 2015/16 year. Contractors represent a minority of CSL's total workforce. We intend to report on total contractors in 2016/17. The manufacture of influenza vaccine is driven by demand in the Northern and Southern Hemispheres and may require CSL to adjust its workforce to meet production and supply commitments.
G4-11	Coverage of collective bargaining agreements	Section 1.5
G4-12	Supply chain	Section 1.2
G4-13	Changes during the reporting period	About this report
G4-14	Precautionary approach or principle	Refer to CSL's Risk Framework in our 2015-2016 Annual Report page 50 on our website www.csl.com.au
G4-15	External sustainability initiatives subscribed to	As listed throughout the document.
G4-16	Association and advocacy organisations	As listed throughout the document.
Identified Material Aspects and Boundaries		
G4-17	List of entities in the financial statements	Section 1.1 and CSL's 2015-2016 Annual Report page 86, on our website http://www.csl.com.au/docs/527/647/CSL_AR16_Sec.0.pdf
G4-18	Process for defining report content and boundaries	Section 1.3, 1.4
G4-19	Material aspects/issues	Section 1.4
G4-20	Aspect boundaries for material aspects/issues within CSL	Section 1.4
G4-21	Aspect boundaries for material aspects/issues outside CSL	Section 1.4
G4-22	Impacts of restatements	About this report
G4-23	Significant changes in scope and aspect boundaries	About this report
Stakeholder Engagement		
G4-24	Stakeholder groups engaged	Section 1.3
G4-25	Identification and selection of stakeholders	Section 1.3
G4-26	Approach to stakeholder engagement	Section 1.3
G4-27	Key topics and concerns raised by stakeholders	Section 1.3
Report Profile		
G4-28	Reporting period	About this report
G4-29	Date of most recent report	About this report
G4-30	Reporting cycle	About this report

G4-31	Contact point for the report	About this report
G4-32	GRI Content Index for 'in accordance – core' option	Available on our website http://corporateresponsibility.csl.com.au/
G4-33	External assurance	About this report
Governance		
G4-34	Governance and structure of the organisation	Refer to CSL's Corporate Governance Statement, available on our website http://annualreport.csl.com.au/our-company/corporate-governance.htm
Ethics and Integrity		
G4-56	Description of the organisation's values and principles	Section 1.3

Specific Standard Disclosures		
Material Aspect	DMA and Indicator * Indicates a CSL developed indicator that is not covered by GRI G4.	CSL's Response
Product Safety and Quality	DMA	Section 3, 3.2, 3.3
	PR2	Section 3.1
Conduct of Clinical Trials	DMA	Section 2.2
	Number of regulatory agency inspections*	Section 2.2
Ethical Marketing	DMA	Section 4.6
	PR7	Section 4.6
Plasma Donations	DMA	Section 3.2
	Percentage of surveyed plasma donors willing to donate again*	Section 3.2
Bribery and Corruption	DMA	Section 4.4
	SO3	Section 4.4
Innovation Process and Management	DMA	Section 2
	Investment spend, number of clinical trials in operation, number product registrations or new indications*	Section 2.1
Anti-Competitive Behaviour	DMA	Section 4.2
	SO7	Section 4.2
Sole Supplier of Critical Medical Products	DMA	Section 3.4
	Status of CSL's watch-list of products.	Section 3.4
Human Rights	DMA	Section 1.5 and 3.4
	Steps taken to prevent and mitigate modern slavery in our direct operations and in the supply chain*	Section 1.5 and 3.4
Data Protection and Privacy	DMA	Section 4.7
	PR8	Data for this indicator is not available. CSL is exploring possible performance indicators that best reflect our priority areas in respect of the management of this aspect. We seek to disclose performance indicators in 2016/17.
Access to Medicines	DMA	Section 4.5
	Support for access programs in developing countries*	Section 4.5 and 5.2
Transparency of Interactions with Government	DMA	Section 4.3
	SO6	Section 4.3 CSL does not undertake in-kind contributions and data for indirect contributions is not available. Support for trade associations is typically untied and industry related. Full disclosure of our policy positions and advocacy, where trade associations and/or charities may be involved, is detailed in section 4.3.

Targeted Community Support	DMA	Section 5
	Investment across key priority areas*	Section 5.1
Counterfeit Medicines	DMA	Section 3.5
	Instances of counterfeit medicines*	Section 3.5